Independent Research, Turtles all the way down

Turtles all the way down

Independent Research

Writing short articles about mis-priced boring stocks around the world.

Equity Bottom-Up

<ul><li>Rain Oncology (RAIN) is being bought out for $1.16 + CVR worth up to $0.17/share.</li><li>This seems like a worse deal than the $1.25 + CVR Tang was offering, but ok, I will take it.</li><li>Usually these CVR’s should be valued at a large discount to their upper value, so I see no reason to hang around in this one so closing this one for a 15% gain at $1.</li></ul>

Rain Oncology (RAIN) is being bought out for $1.16 + CVR worth up to $0.17/share.This seems like a worse deal than the $1.25 + CVR Tang was offering, but ok, I will take it.Usually these CVR’s should be valued at a large discount to their upper value, so I see no reason to hang around in this one so closing this one for a 15% gain at $1.

United States

Rain Oncology Inc. operates as a clinical stage biotechnology company. The Company develops and produces biomarker-driven small molecule therapeutics for patients with cancer and other related diseases. Rain Oncology serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Rain Oncology (RAIN US)

Closing RAIN

Rain Oncology (RAIN) is being bought out for $1.16 + CVR worth up to $0.17/share. This seems like a worse deal than the $1.25 + CVR Tang was...

Turtles all the way down

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)